Mesenchymal stromal cell‐derived extracellular vesicles for regenerative therapy and immune modulation: Progress and challenges toward clinical application

Stem Cells Translational Medicine

Manoj Lalu¹  David Allan²  Dylan Burger³  Alvin Tieu³ 

[1] Clinical Epidemiology Ottawa Hospital Research Institute Ottawa Ontario Canada;Hematology and Blood and Marrow Transplantation The Ottawa Hospital Ottawa Ontario Canada;Regenerative Medicine Programs Ottawa Hospital Research Institute Ottawa Ontario Canada;

关键词: extracellular vesicles;    immune modulation;    mesenchymal stromal cells;    preclinical;    regenerative therapy;   

DOI  :  10.1002/sctm.19-0114

来源: DOAJ

【 摘 要 】

Abstract Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have emerged as a promising form of regenerative therapy and immune modulation. Fundamental advances in our understanding of MSCs and EVs have allowed these fields to merge and create potential cell‐free therapy options that are cell‐based. EVs contain active cargo including proteins, microRNA, and mRNA species that can impact signaling responses in target cells to modify inflammatory and repair responses. Increasing numbers of preclinical studies in animals with various types of injury models have been published that demonstrate the potential impact of MSC‐EV therapy. Although the emergence of registered clinical protocols suggests translation to clinical application has already begun, several barriers to more widespread clinical adoption remain. In this review, we highlight the progress made in MSC‐derived small EV‐based therapy by summarizing aspects pertaining to the starting material for MSC expansion, EV production, and isolation methods, studies from preclinical models that have established a foundation of knowledge to support translation into the patient setting, and potential barriers to overcome on the path to clinical application.

【 授权许可】

Unknown